These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 9751088

  • 1. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?
    Felson DT, Anderson JJ, Lange ML, Wells G, LaValley MP.
    Arthritis Rheum; 1998 Sep; 41(9):1564-70. PubMed ID: 9751088
    [Abstract] [Full Text] [Related]

  • 2. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response.
    American College of Rheumatology Committee to Reevaluate Improvement Criteria.
    Arthritis Rheum; 2007 Mar 15; 57(2):193-202. PubMed ID: 17330293
    [Abstract] [Full Text] [Related]

  • 3. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration.
    Anderson JJ, Wells G, Verhoeven AC, Felson DT.
    Arthritis Rheum; 2000 Jan 15; 43(1):22-9. PubMed ID: 10643696
    [Abstract] [Full Text] [Related]

  • 4. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.
    Pincus T, Strand V, Koch G, Amara I, Crawford B, Wolfe F, Cohen S, Felson D.
    Arthritis Rheum; 2003 Mar 15; 48(3):625-30. PubMed ID: 12632413
    [Abstract] [Full Text] [Related]

  • 5. Continuous indices of core data set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria.
    Pincus T, Amara I, Koch GG.
    Arthritis Rheum; 2005 Apr 15; 52(4):1031-6. PubMed ID: 15818698
    [Abstract] [Full Text] [Related]

  • 6. Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study.
    Anderson JJ, Bolognese JA, Felson DT.
    Arthritis Rheum; 2003 Nov 15; 48(11):3031-8. PubMed ID: 14613263
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
    Ogrendik M.
    Clin Ther; 2009 Aug 15; 31(8):1754-64. PubMed ID: 19808134
    [Abstract] [Full Text] [Related]

  • 8. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
    Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V.
    Arthritis Rheum; 2004 Feb 15; 50(2):364-71. PubMed ID: 14872477
    [Abstract] [Full Text] [Related]

  • 9. Criteria for improvement in rheumatoid arthritis: alternatives to the American College of Rheumatology 20.
    Albert DA, Huang G, Dubrow G, Brensinger CM, Berlin JA, Williams HJ.
    J Rheumatol; 2004 May 15; 31(5):856-66. PubMed ID: 15124243
    [Abstract] [Full Text] [Related]

  • 10. American College of Rheumatology criteria for improvement in rheumatoid arthritis should only be calculated from scores that decrease on improvement.
    Boers M, Verhoeven AC, van der Linden S.
    Arthritis Rheum; 2001 May 15; 44(5):1052-5. PubMed ID: 11352236
    [Abstract] [Full Text] [Related]

  • 11. Estimates of the discriminant ability of definitions of improvement for juvenile rheumatoid arthritis.
    Moroldo MB, Giannini EH.
    J Rheumatol; 1998 May 15; 25(5):986-9. PubMed ID: 9598903
    [Abstract] [Full Text] [Related]

  • 12. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, McCabe D.
    Arthritis Rheum; 2002 Mar 15; 46(3):614-24. PubMed ID: 11920396
    [Abstract] [Full Text] [Related]

  • 13. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
    Sesin CA, Bingham CO.
    Semin Arthritis Rheum; 2005 Dec 15; 35(3):185-96. PubMed ID: 16325659
    [Abstract] [Full Text] [Related]

  • 14. Clinical trial design for evaluating combination therapies.
    Paulus HE.
    Br J Rheumatol; 1995 Nov 15; 34 Suppl 2():92-5. PubMed ID: 8535656
    [Abstract] [Full Text] [Related]

  • 15. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study.
    Lehman AJ, Esdaile JM, Klinkhoff AV, Grant E, Fitzgerald A, Canvin J, METGO Study Group.
    Arthritis Rheum; 2005 May 15; 52(5):1360-70. PubMed ID: 15880810
    [Abstract] [Full Text] [Related]

  • 16. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
    Seitz M, Zwicker M, Villiger PM.
    J Rheumatol; 2003 Jan 15; 30(1):28-35. PubMed ID: 12508386
    [Abstract] [Full Text] [Related]

  • 17. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group.
    Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, Dorrier C, Thompson A.
    Arthritis Rheum; 2000 Mar 15; 43(3):506-14. PubMed ID: 10728742
    [Abstract] [Full Text] [Related]

  • 18. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group.
    Arthritis Rheum; 2006 Sep 15; 54(9):2793-806. PubMed ID: 16947627
    [Abstract] [Full Text] [Related]

  • 19. Etanercept in severe active rheumatoid arthritis: first Australian experience.
    Perera LC, Tymms KE, Wilson BJ, Shadbolt B, Brook AS, Dorai Raj AK, Khoo KB.
    Intern Med J; 2006 Oct 15; 36(10):625-31. PubMed ID: 16958637
    [Abstract] [Full Text] [Related]

  • 20. Effects of clarithromycin in patients with active rheumatoid arthritis.
    Ogrendik M.
    Curr Med Res Opin; 2007 Mar 15; 23(3):515-22. PubMed ID: 17355733
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.